C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. 

The institutes have led over 1,000 studies, published 5,500 manuscripts (including 144 in the New England Journal) and have led 60 FDA submissions from their network of 7,000 sites worldwide. Gibson has been ranked as one of the world's most highly cited authors in all of science. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 136,000 times, and he has an H index of 129 and an i10-index of 523. 

Dr. Gibson is a practicing interventional cardiologist who has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians. 

Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban, and andexanet as well as devices such as one that alarms to alert a patient to heart attack. 

For years, Gibson has been chosen as one of Boston's Top Doctors. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times), the TIMI myocardial perfusion grade (cited 1,089 times). 

Dr. Gibson obtained his BS, MS, and MD degrees at the University of Chicago. He then went on to do his internship, residency and chief residency at the Brigham and Women's Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School.